The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.00
Bid: 18.50
Ask: 19.50
Change: -0.25 (-1.30%)
Spread: 1.00 (5.405%)
Open: 19.25
High: 19.25
Low: 19.00
Prev. Close: 19.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of NED

7 Jan 2013 07:00

RNS Number : 9111U
Angle PLC
07 January 2013
 



For immediate release

 7 January 2013

 

ANGLE plc

("ANGLE" or "the Company")

 

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

 

 

ANGLE plc (AIM: AGL), the specialist medtech company, is pleased to announce the appointment of Brian Howlett as a Non-Executive Director of the Company. The appointment is effective immediately.

 

Brian has more than 20 years' experience of building and managing medical device and diagnostic businesses, and prior to this he worked in the pharmaceutical industry.

 

Brian was CEO of AIM-quoted Lombard Medical Technologies PLC from 2005 to 2010, during which time he took the company from the development stage to product sales. He also raised a total of £49 million in equity funding in challenging financial markets.

 

From 1999 to 2005, Brian was UK Country Leader at Boston Scientific Corporation, where he was responsible for launching a number of new medical devices into the UK market. From 1987 to 1999 he was Managing Director of Cobe Laboratories Limited where he achieved significant growth in the Renal Care, Cardiovascular and Blood Component Technology (BCT) divisions.

 

Since 2010, Brian has been Non-Executive Chairman of two privately held companies, Michelson Diagnostics Limited and Vascular Flow Technologies Limited. He is also a Non-Executive Director of privately held company Accentus Limited.

 

 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"Brian brings a wealth of business experience to ANGLE and a deep understanding of the medical diagnostic market, including product development, regulatory approvals, major corporate deals and sales strategies. We look forward to working with Brian in the continuing development of ANGLE's business."

 

 

Brian Howlett, age 68, does not currently hold shares in ANGLE. There are no further disclosures to be made in relation to Mr Howlett under Schedule 2(g) and (i) of the AIM rules.

 

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts, Christian Hobart (Sales)

 

020 7397 8900

Buchanan

Mark Court, Fiona Henson, Sophie Cowles

 

020 7466 5000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADMGGMLVFGFZM
Date   Source Headline
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.